J.P. Morgan analyst Anupam Rama has maintained their bullish stance on TVTX stock, giving a Buy rating on November 7.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Anupam Rama’s rating is based on several compelling factors surrounding Travere Therapeutics. The potential approval of Filspari for the treatment of FSGS is a significant driver, as key opinion leaders at a recent conference indicated that the drug would see widespread and rapid adoption upon approval. This sentiment is supported by data from the DUPLEX study, which demonstrated that Filspari significantly reduced proteinuria compared to irbesartan, suggesting a strong therapeutic benefit.
Additionally, the positive reception of Filspari in treating IgAN, where it is preferred over Vanrafia due to full approval and real-world experience, further supports the Buy rating. The modifications in the REMS for Filspari have not hindered its utilization, indicating that the drug’s market potential remains robust. These factors, combined with the strategic attractiveness of Travere as a company, underpin Anupam Rama’s optimistic outlook on the stock.
In another report released on November 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $47.00 price target.
TVTX’s price has also changed dramatically for the past six months – from $20.230 to $32.340, which is a 59.86% increase.